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Roberts ZS, Wolden-Hanson T, Matsen ME, Ryu V, Vaughan
CH, Graham JL, Havel PJ, Chukri DW, Schwartz MW, Morton
GJ, Blevins JE. Chronic hindbrain administration of oxytocin is
sufficient to elicit weight loss in diet-induced obese rats. Am J Physiol
Regul Integr Comp Physiol 313: R357–R371, 2017. First published
July 20, 2017; doi:10.1152/ajpregu.00169.2017.—Oxytocin (OT) ad-
ministration elicits weight loss in diet-induced obese (DIO) rodents,
nonhuman primates, and humans by reducing energy intake and
increasing energy expenditure. Although the neurocircuitry underly-
ing these effects remains uncertain, OT neurons in the paraven-
tricular nucleus are positioned to control both energy intake and
sympathetic nervous system outflow to interscapular brown adi-
pose tissue (BAT) through projections to the hindbrain nucleus of
the solitary tract and spinal cord. The current work was undertaken
to examine whether central OT increases BAT thermogenesis,
whether this effect involves hindbrain OT receptors (OTRs), and
whether such effects are associated with sustained weight loss
following chronic administration. To assess OT-elicited changes in
BAT thermogenesis, we measured the effects of intracerebroven-
tricular administration of OT on interscapular BAT temperature in
rats and mice. Because fourth ventricular (4V) infusion targets
hindbrain OTRs, whereas third ventricular (3V) administration
targets both forebrain and hindbrain OTRs, we compared responses
to OT following chronic 3V infusion in DIO rats and mice and
chronic 4V infusion in DIO rats. We report that chronic 4V
infusion of OT into two distinct rat models recapitulates the effects
of 3V OT to ameliorate DIO by reducing fat mass. While reduced
food intake contributes to this effect, our finding that 4V OT also
increases BAT thermogenesis suggests that increased energy ex-
penditure may contribute as well. Collectively, these findings
support the hypothesis that, in DIO rats, OT action in the hindbrain
evokes sustained weight loss by reducing energy intake and in-
creasing BAT thermogenesis.
obesity; brown adipose tissue; thermogenesis; oxytocin
GROWING EVIDENCE SUGGESTS that central release of the neuro-
hypophyseal hormone oxytocin (OT), which is produced pre-
dominantly by neurons in the hypothalamic supraoptic nucleus
(SON) and paraventricular nucleus (PVN), plays an important
role in energy homeostasis (3). Thus, either central or systemic
OT can reduce body weight (or body weight gain) in diet-
induced obese (DIO) and genetically obese rodent models (1,
7, 17, 33, 35, 40, 45). The translational relevance of these
observations was recently buttressed by their successful trans-
lation to DIO nonhuman primates (4) and obese humans (32,
56, 61).
The dose-dependent reduction of food intake by OT,
whether administered systemically, intranasally, or directly
into the central nervous system (CNS), is well documented (3),
and while this effect undoubtedly contributes to OT-induced
weight loss (4, 7, 17, 33, 59), mounting evidence implies a role
for increased energy expenditure (EE) as well. Weight loss
elicited by OT exceeds that of pair-fed controls (17, 40).
Furthermore, acute third ventricular (3V) or subcutaneous
administration of OT increases EE in mice (59, 60) and
nonhuman primates (4). Similarly, acute chemogenetic stim-
ulation of PVN OT neurons with use of designer receptors
exclusively activated by designer drugs (DREADDs) tech-
nology increases both EE and interscapular brown adipose
tissue (IBAT) temperature (TIBAT, a functional readout of
BAT thermogenesis) in Oxytocin-Ires-Cre mice (53a). Con-
versely, reduced OT signaling is associated with obesity
(11, 54, 58, 60), despite the absence of hyperphagia (11, 54),
suggesting that EE must also be reduced in this setting (29,
58 – 60). Indeed, defects in BAT thermogenesis are reported
in such models (29, 30). Collectively, these findings support
a role for increased BAT thermogenesis in OT-elicited
weight loss.
The OT receptor (OTR) populations that mediate the effects
of exogenous OT on energy intake and EE remain uncertain.
Much work in this field has focused on 3V administration of
OT, which reduces high-fat diet (HFD) intake (7, 59, 60),
increases EE (59, 60), and evokes weight loss (7, 59, 60), but
this route of administration targets OTRs in forebrain and
hindbrain and, hence, cannot distinguish between the two
regions. In contrast, infusion into the fourth ventricle (4V)
targets hindbrain OTRs. Therefore, we sought to determine
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whether chronic hindbrain (4V) OT recapitulates the ability of
3V OT to elicit sustained weight loss in rodent models of DIO.
We also measured TIBAT during central OT administration to
investigate whether OT-elicited weight loss is associated with
increased BAT thermogenesis and, if so, whether this effect
involves activation of hindbrain OTRs.
Our findings demonstrate that, in a rat model of DIO,
chronic hindbrain (4V) administration of OT recapitulates the
effects of 3V infusions to reduce both HFD consumption and
body fat mass while also elevating TIBAT. We also confirm that
OT-mediated stimulation of IBAT thermogenesis involves an
OTR-dependent mechanism by showing that the effect is
blocked by pretreatment with an OTR antagonist. Collectively,
these findings support the hypothesis that sustained weight loss
elicited by OT action in the hindbrain in DIO rats likely




Adult male Sprague-Dawley (CD IGS) rats (6.6–7.5 mo old,
477–885 g body wt) and Long-Evans rats (3–9.25 mo old, 331–781 g
body wt) were obtained from Charles River Laboratories International
(Wilmington, MA) or Envigo (Indianapolis, IN). C57BL/6J mice
(5.25–6.5 mo old, 25.7–51.3 g body wt) were obtained from The
Jackson Laboratory (Bar Harbor, ME). CD IGS rats were used to
determine the effect of chronic 4V infusion of OT relative to that of
3V infusion, as previously described (7). The Long-Evans rat strain
was chosen by design, given that it is a well-characterized rat model
of DIO (55). To determine if these effects occurred across species,
additional studies were conducted in C57BL/6J mice. All animals
were housed individually in Plexiglas cages in a temperature-con-
trolled (22 2°C) room under a 12:12-h light-dark cycle (lights off at
1 PM). Rats and mice had ad libitum access to water and either a HFD
containing 60% of kilocalories from fat (diet no. D12492, Research
Diets, New Brunswick, NJ) or a low-fat chow diet containing 13%
(rats; diet no. 5001, LabDiet, St. Louis, MO) or 16% (mice; diet no.
5LG4, LabDiet) of kilocalories from fat, unless otherwise stated.
Kaolin pellets were also purchased from Research Diets. The research
protocols were approved by the Institutional Animal Care and Use
Committee of the Veterans Affairs Puget Sound Health Care System
(VAPSHCS) and the University of Washington in accordance with
National Institutes of Health guidelines for the care and use of
animals.
Drug Preparation
Fresh solutions of OT acetate salt (Bachem Americas, Torrance,
CA) or the OTR antagonist (d(CH2)51,Tyr(Me)2,Orn8)-oxytocin trif-
luoroacetate salt (Bachem Americas) were prepared on the day of
each experiment. OT and the OTR antagonist were solubilized in
sterile water; OT was further diluted with sterile saline.
3V or 4V Cannulations for Acute Injections
Animals were implanted with a cannula that was directed toward
the 3V or 4V, as previously described (6, 7, 39). Briefly, rats or mice
under isoflurane anesthesia were placed in a stereotaxic apparatus,
with the incisor bar positioned below (3.3 mm for rats or 4.5 mm for
mice) the interaural line. A 26-gauge cannula (Plastics One) was
stereotaxically positioned into the 3V (rat: 7.3 anterior to the interau-
ral line, 0 mm lateral to the midline, and 7.6 mm ventral to the skull
surface; mouse: 1.5 posterior to bregma, 0 mm lateral to the midline,
and 4 mm ventral to the skull surface) or 4V (rat: 3.5 posterior to
bregma, 1.4 mm lateral to the midline, and 6.2 mm ventral to the skull
surface) and secured to the surface of the skull with dental cement and
stainless steel screws.
3V or 4V Cannulations for Chronic Infusions
Rats. Briefly, rats were implanted with a cannula within the 3V or
4V with a side port that was connected to an osmotic minipump
(model 2004, DURECT, Cupertino, CA), as previously described (7).
For rats, we followed the protocol for acute injections described
above, except 28-gauge cannulas were placed 1 mm further ventral to
the skull surface. The 3V coordinate for the CD IGS rat was also
adjusted to 8.1 anterior to the interaural line. A 2.4-inch piece of
plastic tubing (Tygon microbore tubing, 0.020  0.060 inch OD;
Cole-Parmer, Vernon Hills, IL) was tunneled subcutaneously along
the midline of the back and connected to the 21-gauge sidearm
osmotic minipump-cannula assembly. A stainless steel 22-gauge pin
plug (Instech Laboratories, Plymouth Meeting, PA) was inserted at
the end of the tubing (backfilled with sterile saline) during a 2-wk
postoperative recovery period, after which it was replaced by an
osmotic minipump (DURECT) containing saline or OT. Rats were
treated with the analgesic buprenorphine SR LAB [sustained release
(0.65–1 mg/kg); ZooPharm, Windsor, CO] and the antibiotic enro-
floxacin (5 mg/kg; Baytril, Patterson Veterinary, Devens, MA) at the
completion of the 3V and 4V cannulations and allowed to recover for
10 days before implantation of osmotic minipumps.
Mice. Briefly, mice were implanted with a cannula within the 3V
with a side port that was connected to an osmotic minipump (model
2004, DURECT), as previously described (18). Mice under isoflurane
anesthesia were placed in a stereotaxic apparatus, with the incisor bar
positioned 4.5 mm below the interaural line. A 30-gauge cannula
(Plastics One) was stereotaxically positioned into the 3V (1.5 mm
caudal to bregma, 0 mm lateral to the midline, and 5 mm ventral to the
skull surface) and secured to the surface of the skull with dental
cement and stainless steel screws. A 1.2-inch piece of plastic Tygon
microbore tubing (0.020  0.060 inch OD; Cole-Parmer) was tun-
neled subcutaneously along the midline of the back and connected to
the 21-gauge sidearm osmotic minipump-cannula assembly. A stain-
less steel 22-gauge pin plug (Instech Laboratories) was inserted at the
end of the tubing during a 2-wk postoperative recovery period, after
which it was replaced by an osmotic minipump (DURECT) contain-
ing saline or OT. Mice were treated with the analgesic ketoprofen (5
mg/kg; Fort Dodge Animal Health) and the antibiotic Baytril (5
mg/kg; Patterson Veterinary) at the completion of the 3V cannulations
and allowed to recover for 10 days before implantation of osmotic
minipumps.
Implantation of Temperature Transponders Beneath IBAT
Animals were anesthetized with isoflurane, the dorsal surface along
the upper midline of the back was shaved, and the area was scrubbed
with betadine followed by 70% ethanol. A 1-inch incision was made
at the midline of the interscapular area. The temperature transponder
(14 mm long  2 mm wide; model HTEC IPTT-300, Bio Medic Data
Systems, Seaford, DE) was implanted under one (rat) or both (mouse)
IBAT pads, as previously described (9, 57), and secured in place by
sterile silk suture. The interscapular incision was closed with standard
metal wound clips, which were removed in awake animals 10–14
days after surgery.
Acute 3V or 4V Injections and Measurements of TIBAT in Rats
and Mice
OT (or saline vehicle, 1-l injection volume) was administered
immediately before the start of the dark cycle following 6 h of food
deprivation in rats or mice. Animals remained without access to food
for an additional 4 h during the course of the TIBAT measurements. A
hand-held reader (DAS-7007R round implantable programmable tem-
perature transponder wireless reader system, Bio Medic Data Sys-
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tems) was used to collect measurements of TIBAT in rats and mice.
The 3V and 4V injections were administered at 1 l/min via an
injection pump (model 100 syringe pump, CMA Microdialysis) with
a 33-gauge injector (Plastics One) connected by polyethylene-20
tubing to a 10-l Hamilton syringe. Animals underwent all treatment
conditions (unless otherwise noted) in a randomized order, with 48
h between treatments. Dose-response studies were conducted to de-
termine a subthreshold dose of the OTR antagonist to use for the
experiment.
Body Composition
Lean body mass and fat mass of unanesthetized rats and mice were
determined by quantitative magnetic resonance (EchoMRI-700 4-in-1,
Echo Medical Systems, Houston, TX) at the VAPSHCS Rodent
Metabolic and Behavioral Phenotyping Core.
Study Protocols
Study 1A: effects of chronic 3V OT infusions on energy intake, body
weight, and body composition in DIO and chow-fed Long-Evans rats.
Ad libitum-fed rats were maintained on chow or the HFD for 4 and 4.5
mo before implantation of 3V cannulas and 28-day minipumps to
infuse vehicle or OT (16 nmol/day) over 27 or 28 days. Daily energy
intake and body weight were recorded on days 1–27.
Study 1B: effects of 3V treatment cessation on energy intake, body
weight gain, and body composition in DIO Long-Evans rats. After
completion of study 1A on day 27 or 28, minipumps were removed
from a subset of DIO animals under isoflurane anesthesia. Daily
energy intake and body weight were recorded in 3-h fasted animals for
an additional 27 days.
Study 2A: effects of chronic 3V OT infusions on energy intake, body
weight, and body composition in DIO and chow-fed mice. Ad libitum-
fed mice were maintained on chow or the HFD for 4 and 4.5 mo
before implantation of 3V cannulas and 28-day minipumps for infu-
sion of vehicle or OT (16 nmol/day) over 28 days, respectively. Daily
energy intake and body weight were recorded on days 1–28.
Study 2B: effect of chronic 3V OT infusions on kaolin consumption
in DIO mice. Kaolin intake (g) was assessed across 15 days following
implantation of minipumps containing vehicle (saline) or OT (16
nmol/day). Placement of kaolin and chow was reversed every other
day within each treatment condition.
Study 3A: effects of chronic 4V OT infusions on energy intake, body
weight, and body composition in DIO and chow-fed CD IGS rats. Ad
libitum-fed rats were maintained on chow or the HFD for 4 and 4.5
mo before implantation of 4V cannulas and 28-day minipumps for
infusion of vehicle or OT (16 nmol/day) over 27 days, respectively.
Daily energy intake and body weight were recorded on days 1–27.
Study 3B: effect of chronic 4V OT infusions on kaolin consumption
in DIO CD IGS rats. Kaolin intake (g) was assessed across 27 days
following implantation of minipumps containing vehicle (saline) or
OT (16 nmol/day). Placement of kaolin and chow was reversed every
other day within each treatment condition.
Study 3C: effects of 4V treatment cessation on energy intake, body
weight gain, and body composition in DIO CD IGS rats. After
completion of study 3A on day 27, minipumps were removed from a
subset of DIO animals under isoflurane anesthesia. Daily energy
intake and body weight were recorded in 3-h-fasted animals for an
additional 27 days.
Study 4A: effects of chronic 4V OT infusions on energy intake, body
weight, and body composition in DIO Long-Evans rats. Ad libitum-
fed rats were maintained on chow or the HFD for 4 and 4.5 mo before
implantation of 4V cannulas and 28-day minipumps for infusion of
vehicle or OT (16 nmol/day) over 27 days, respectively. Daily energy
intake and body weight were recorded on days 1–27.
Study 4B: effects of 4V treatment cessation on energy intake, body
weight gain, and body composition in DIO Long-Evans rats. After
completion of study 4A on day 27, minipumps were removed from a
subset of DIO animals under isoflurane anesthesia. Daily energy
intake and body weight were recorded in 3-h-fasted animals for an
additional 27 days.
Study 5: effects of acute 3V OT administration on TIBAT in rats and
mice. 3V cannulas and temperature transponders were implanted in
rats and mice. After adaptation to a 6-h fast and handling, vehicle or
OT [1 and 5 g/l (rats), 5 g/l (mice)] was injected into the 3V
immediately before the start of the dark cycle in a crossover design at
48-h intervals, such that each animal served as its own control. TIBAT
was measured at baseline (2 h), immediately before 3V injections
(0 h), and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, and 18 h postinjection.
Study 6A: effects of acute 4V OT administration on TIBAT in rats.
4V cannulas and temperature transponders were implanted in rats.
After adaptation to a 6-h fast and handling, vehicle or OT (1 and 5
g/l) was injected into the 4V immediately before the start of the
dark cycle in a crossover design at 48-h intervals, such that each
animal served as its own control. TIBAT was measured at baseline (2
h), immediately before 4V injections (0 h), and at 0.25, 0.5, 0.75, 1,
1.25, 1.5, 2, 3, 4, and 18 h postinjection.
Study 6B: effects of 4V OT administration on TIBAT following 4V
OT antagonist treatment in rats. 4V cannulas and temperature tran-
sponders were implanted in rats. After adaptation to a 6-h fast and
handling, vehicle (2 l) or the OT receptor antagonist (10 g in 2 l)
was injected into the 4V 30 min before OT (5 g/l) in a crossover
design at 48-h intervals, such that each animal served as its own
control. As described above, TIBAT was measured at baseline (2 h),
immediately before 4V injections (0 h), and at 0.25, 0.5, 0.75, 1, 1.25,
1.5, 2, 3, 4, and 18 h postinjection.
Study 6C: effects of acute 4V OT administration on TIBAT in DIO
rats. 4V cannulas and temperature transponders were implanted in
rats. After adaptation to a 6-h fast and handling, vehicle or OT (1 and
5 g/l) was injected into the 4V immediately before the start of the
dark cycle in a crossover design at 48-h intervals, such that each
animal served as its own control. TIBAT was measured at baseline (2
h), immediately before 4V injections (0 h), and at 0.25, 0.5, 0.75, 1,
1.25, 1.5, 2, 3, 4, and 18 h postinjection.
Study 6D: effects of chronic 3V OT administration on TIBAT in DIO
rats. 3V cannulas and temperature transponders were implanted in a
subset of rats from study 1A. TIBAT was measured once daily over the
first 3 days of the infusion period in 3-h-fasted rats.
Blood Collection
Blood was collected from 3-h-fasted rats and mice at the end of the
light cycle within a 2-h window (10:00 AM–12:00 PM), as previously
described in DIO CD IGS rats (7). Treatment groups were counter-
balanced at euthanasia to avoid bias. Blood samples [up to 3 ml (rats)
or 0.5 ml (mice)] were collected immediately before transcardial
perfusion by cardiac puncture in chilled serum separator tubes (Amber
SST, Becton Dickinson, Franklin Lakes, NJ). Whole blood was
centrifuged at 6,000 rpm for 1.5 min at 4°C; serum was removed,
separated into aliquots, and stored at 80°C for analysis.
Serum Hormone Measurements
Serum leptin was measured using electrochemiluminescence de-
tection [Meso Scale Discovery (MSD), Rockville, MD] using estab-
lished procedures (8). Intra-assay coefficient of variation (CV) for
leptin was 3.9%. The range of detectability for the leptin assay is
0.055–100 ng/ml. Serum fibroblast growth factor-21 (FGF-21; R & D
Systems, Minneapolis, MN) and irisin (AdipoGen, San Diego, CA)
levels were determined by ELISA. The intra-assay CVs for FGF-21
and irisin were 4.3 and 4.1%, respectively; the ranges of detectability
were 13.4–2,000 pg/ml for FGF-21 and 0.1–5 g/ml for irisin. Data
were normalized to historical values using a pooled plasma quality-
control sample that was assayed in each plate.
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Blood Glucose and Lipid Measurements
Blood was collected for glucose measurements by tail vein nick
and measured using a glucometer and a blood glucose monitoring
system (AlphaTRAK 2, Abbott Laboratories, Abbott Park, IL) (7).
Total cholesterol (TC) and free fatty acids (FFAs) were measured
using an enzymatic-based kit (Wako Chemicals USA, Richmond,
VA). Intra-assay CVs for TC and FFAs were 1.2 and 1.1%, respec-
tively. These assay procedures have been validated for rodents (16).
Statistical Analyses
Values are means SE. Comparisons between multiple groups
involving between-subjects designs were made using one- or two-way
ANOVA as appropriate, followed by a post hoc Fisher’s least signif-
icant difference test. Comparisons involving within-subjects designs
were made using a one-way repeated-measures ANOVA followed by
a post hoc Fisher’s least significant difference test. Analyses were
performed using the statistical program SYSTAT (Systat Software,
Point Richmond, CA). Differences were considered significant at P
0.05 (2-tailed).
RESULTS
Study 1A: Effects of Chronic 3V OT Infusions on Energy
Intake, Body Weight, and Body Composition in DIO and
Chow-Fed Long-Evans Rats
Our previous work demonstrates that chronic 3V OT admin-
istration is sufficient to prevent and reverse DIO in CD IGS rats
(7). To determine if this effect is consistent across other DIO
rat models, we studied Long-Evans rats, which exhibit in-
creased susceptibility to DIO (55) and are widely used in the
literature. As expected, Long-Evans rats fed the HFD for 4.5
mo gained more weight (600  12 vs. 519  13 g) and exhib-
ited greater adiposity (192  9 vs. 92  9 g) than chow-fed
controls (P 0.05) before 3V administration of OT or vehicle.
Whereas rats maintained on the HFD and treated with 3V
vehicle continued to gain weight throughout the 28-day study
period, rats maintained on the HFD and treated with 3V OT
exhibited marked reductions of total body weight (6.3%; Fig.
1A) and weight gain (Fig. 1B) relative to baseline values (P 
0.05). This effect was associated with sustained reductions of fat
mass gain (Fig. 1C; P  0.05) and serum leptin levels (Table 1),
with no decrease in lean mass gain. As expected, a sustained
reduction of energy intake was associated with these OT-mediated
changes in body weight and composition (Fig. 1D; P  0.05).
To determine if these effects of OT depend on nutritional
status, the above-described studies were repeated in age-
matched nonobese chow-fed rats. While body weight gradually
increased throughout the 28-day study period in the 3V-vehicle
group, but not the 3V-OT group (Fig. 1E; P  0.05), 3V OT
did not induce weight loss [Fig. 1, E and F; P not significant
(NS)], as observed in DIO rats. Furthermore, there were no
differences in fat mass gain or lean mass gain (Fig. 1G; P 
NS) or energy intake (Fig. 1H; P  NS) between 3V-vehicle
and 3V-OT cohorts of chow-fed animals.
At the dose selected for this study (16 nmol/day), therefore,
the effect of 3V OT to elicit reduced fat mass and weight loss
appears selective for rats with DIO; in these animals, loss of
body weight was confined to the adipose tissue compartment,
with no overall effect on lean body mass. Whereas a lower
dose of 3V OT (1.6 nmol/day) was without effect on weight
gain in Long-Evans and CD IGS rats (7) that were maintained
on a HFD but did not have established DIO (data not shown),
a more complete dose-response analysis is needed to determine
if selectivity for DIO holds across effective OT doses.
Study 1B: Effects of 3V Treatment Cessation on Energy
Intake, Body Weight Gain, and Body Composition in DIO
Long-Evans Rats
We previously showed that the reduction of weight gain
following OT treatment persists for ~10 days in CD IGS rats
(7). To determine the durability of effects on energy balance
and body composition following cessation of OT treatment in
Long-Evans rats with DIO, we tracked daily energy intake and
body weight following minipump removal in a subset of
animals used in study 1A. In vehicle-treated animals, body
weight remained stable following minipump removal (on day
27 or 28), as expected. By comparison, body weight signifi-
cantly increased in animals that previously received OT (Fig.
2A; P 0.05) but remained significantly below that of vehicle-
treated controls for the next 12 days (Fig. 2B; P  0.05).
Eventually, however, the effect of 3V OT to reduce body
weight, fat mass, and serum leptin levels (Table 1) in these
animals subsided, with values returning to those of vehicle-
treated controls (Fig. 2C; P  NS). This response appears to
have been driven by a rebound hyperphagia that developed
during the 2nd wk following minipump removal (Fig. 2D).
Serum Hormones Following 3V Vehicle and OT Treatment
and Treatment Cessation in Chow- and HFD-Fed
Long-Evans Rats
To characterize the metabolic effects of 3V OT in DIO and
chow-fed Long-Evans rats, we measured blood glucose levels and
serum concentrations of leptin, insulin, FGF-21, irisin, TC, and
FFAs. At baseline, vehicle-treated DIO animals exhibited in-
creased levels of leptin, insulin, FGF-21, irisin, and TC relative to
chow-fed vehicle-treated animals (P  0.05; Table 1). As ex-
pected, OT treatment was associated with a reduction of serum
leptin in DIO animals (7, 17) (in which fat mass was also
reduced), but not in chow-fed control animals (in which fat mass
was not reduced). As reported earlier (7), 3V OT also reduced
serum TC levels (P 0.05) in DIO, but not chow-fed, animals. In
contrast, OT treatment was not associated with significant changes
in blood glucose levels or serum levels of insulin, FGF-21, irisin,
or FFA in DIO or chow-fed rats. After the washout period,
differences in serum leptin or TC levels between animals that
received OT or vehicle treatment were no longer apparent (P 
NS; Table 1).
Study 2, A and B: Effects of Chronic 3V OT Infusions on
Energy Intake, Body Weight, and Body Composition in DIO
and Chow-Fed Mice
To determine whether the weight-reducing effect of chronic
3V OT infusion in two DIO rat models extends to obese mice,
we repeated these studies in age-matched DIO and chow-fed
C57BL/6J mice. By design, body weight (43.4  1.1 vs.
30.8  0.6 g) and adiposity (17  0.5 vs. 3.7  0.6 g) were
greater (P  0.05) in DIO than chow-fed mice at baseline
(after maintenance on chow or the HFD for 4.5 mo).
In contrast to continuous body weight gain during 3V
vehicle treatment over 28 days in DIO mice maintained on the
HFD (Fig. 3A; P  0.05), 3V OT treatment induced reduc-
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tions of body weight (8.7%; Fig. 3A) and weight gain (Fig.
3B) relative to the start of the infusion period (P  0.05).
There was a significant main effect of OT to reduce fat mass
gain (Fig. 3C; P  0.05), with no effect on lean body mass,
as in DIO rats, effects that were mediated, at least in part, by
a reduction of energy intake over the first 2 wk (Fig. 3D;
P  0.05). These effects do not appear to result from an
aversive effect of 3V OT, since there was no effect on kaolin
consumption (relative to vehicle-treated DIO control mice;
n  3–5/group) during the 12-day measurement period (P 
NS; data not shown). Overall, these findings demonstrate
that the response of DIO mice to 3V OT is similar to that of
Fig. 1. Effects of chronic oxytocin (OT) infu-
sion into the 3rd ventricle (3V) on energy
intake, body weight, and body composition
in diet-induced obese (DIO) and chow-fed
Long-Evans rats. Ad libitum-fed rats were
maintained on the high-fat diet (HFD; 60% of
kcal from fat; n  17–18/group) or chow (n 
6–7/group) for 4.5 mo before receiving contin-
uous infusions of vehicle (Veh) or OT (16
nmol/day). A and E: change in body weight in
HFD-fed DIO and chow-fed control animals. B
and F: change in body weight gain in HFD-fed
DIO and chow-fed control animals. C and G:
change in fat mass and lean mass in HFD-fed
DIO and chow-fed control animals. D and H:
daily energy intake in HFD-fed DIO and chow-
fed control animals. Values are means SE.
*P  0.05, OT vs. vehicle.
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DIO rats and extend previous evidence that neither acute nor
chronic 3V administration of OT affects kaolin consumption
(7, 59).
Similar to our observations in rats, the weight-reducing
effect of 3V OT in HFD-fed DIO mice was not observed in
mice fed standard chow (Fig. 3E; P  NS), although a slight
attenuation of weight gain relative to 3V vehicle-treated con-
trols was observed over the 28-day period (Fig. 3F; P  0.05).
This modest effect was not associated with significant changes
in body fat mass or lean mass (Fig. 3G; P  NS) or energy
intake (Fig. 3H) relative to vehicle-treated controls.
Serum Hormones Following 3V Vehicle and OT Treatment
in Chow- and HFD-Fed DIO Mice
Among animals receiving 3V vehicle, mice maintained on
the HFD exhibited increased levels of blood glucose and serum
leptin, insulin, FGF-21, blood glucose, and TC relative to those
fed standard chow (P 0.05; Table 2). Similar to observations
in the DIO rat model, 3V OT failed to reduce serum insulin
levels but did reduce serum TC levels (P  0.05), whereas
blood glucose and serum levels of leptin, FFA, TG, irisin, and
FGF-21 were not significantly altered.
Study 3A: Effects of Chronic 4V OT Infusions on Energy
Intake, Body Weight, and Body Composition in DIO and
Chow-Fed CD IGS Rats
Given that 1) the 3V route of administration does not
differentiate a forebrain from a hindbrain site of action and 2)
intake of standard chow is acutely inhibited by 4V (27, 43) or
nucleus tractus solitarius (NTS) administration of OT (43), we
sought to determine whether the antiobesity effects of chronic
3V OT administration are replicated by chronic hindbrain (4V)
OT administration in either of two different DIO rat (CD IGS
and Long-Evans) models.
As expected, body weight (738  13 vs. 614  13 g) and fat
mass (226  9 vs. 113  9 g) were greater in CD IGS rats that
had been maintained on the HFD for 4.5 mo than in age-
matched chow-fed rats (P  0.05) at study onset.
Consistent with the response to 3V OT, continuous 4V OT
infusion over 27 days reduced body weight (4.9%; Fig. 4A)
and body weight gain (Fig. 4B) in HFD-fed CD IGS rats (P 
0.05), effects associated with reduced fat mass gain. In contrast
to chronic 3V OT administration, however, 4V OT adminis-
tration also reduced lean mass gain (Fig. 4C; P  0.05). These
effects were again associated with a sustained reduction of
energy intake (Fig. 4D; P 0.05) that was not secondary to an
aversive effect of 4V OT, since kaolin consumption was not
increased (data not shown).
Consistent with results from 3V OT administration, these
effects of chronic 4V OT administration appear to be specific
for DIO animals, since, despite a small transient effect at study
onset, 4V OT did not reduce body weight, fat mass, or energy
intake in chow-fed control CD IGS rats at the dose used (16
nmol/day; Fig. 4, D–G). Future studies are needed to determine
if the diet-selective nature of the response to 4V OT pertains
across the effective dose range.
Table 1. Serum measurements after 3V infusions of OT or vehicle and at washout in DIO rats from study 3A
Chow HFD HFD
Veh OT Veh OT Veh Washout OT Washout
Leptin, ng/ml 10.4 2.4c 7.0  1.6c 28.1  1.9a 18.7  2.4b 28.5  2.3a 31.5  2.5a
Insulin, ng/ml 0.6 0.09c 0.8  0.02a,c 1.3  0.20a,b 1.3  0.23b 4.4  1.30a 5.0  1.38a
FGF-21, pg/ml 51 4.7b 53  14.9b,c 97  12.5a 73  6.1a,b 108  11.4a 108  15.1a
Irisin, g/ml 3.5 0.2b 5.0  0.3a,b 5.7  0.7a 5.7  0.5a 5.3  0.3a 4.4  0.2a
Blood glucose, mg/dl 143 5.3a 143  4.4a 141  3.8a 149  5.5a 137  4.9a 142  5.6a
FFA, meq/l 0.2 0.02b,c 0.1  0.02c 0.3  0.02a 0.2  0.06a,b 0.3  0.06a 0.3  0.03a
Total cholesterol, mg/dl 61 3.2c 61  3.4c,d 85  2.1a 72  3.4b 75  5.5a 81  2.9a
Values means  SE; n  6–7/group for oxytocin (OT)- or vehicle (Veh)-infused rats; n  9–11/group for washout rat. 3V, 3rd ventricle; DIO, diet-induced
obese; HFD, high-fat diet. Different superscript letters denote significant differences between treatments; shared letters denote values that are not significantly
different from one another.
Fig. 2. Effects of 3V OT treatment cessation on energy intake, body weight gain, and body composition in DIO Long-Evans rats. Minipumps were removed on
day 27 (indicated by arrow) from a subset of DIO rats (n  7–11/group) that previously received continuous infusions of vehicle or OT (16 nmol/day). Ad
libitum-fed rats were maintained on the HFD (60% of kcal from fat) throughout the 27-day washout (WO) period. A: change in body weight in HFD-fed DIO
animals during washout. B: change in body weight gain in HFD-fed DIO animals during washout. C: change in fat mass and lean mass in HFD-fed DIO animals
during washout. D: daily energy intake in HFD-fed DIO animals during washout. Values are means SE. *P 0.05, OT vs. vehicle or post-OT vs. postvehicle.
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Overall, these data indicate that chronic 4V delivery of OT
elicits sustained reductions of energy intake, body weight,
weight gain, and fat mass gain in DIO (but not chow-fed) rats.
Since 4V OT had no effect on kaolin intake in HFD-fed rats
and did not suppress energy intake in chow-fed rats, the
substantial weight reduction induced by hindbrain OT action in
this DIO rat model does not appear to involve an aversive
effect.
Fig. 3. Effects of chronic 3V OT infusions on
energy intake, body weight gain, and body
composition in DIO and chow-fed mice. Ad
libitum-fed mice were maintained on the
HFD (60% of kcal from fat; n  7–12/group)
or chow (n  8–9/group) for 4.5 mo before
receiving continuous infusions of vehicle or
OT (16 nmol/day). A and E: change in body
weight in HFD-fed DIO and chow-fed control
animals. B and F: change in body weight gain
in HFD-fed DIO and chow-fed control ani-
mals. C and G: change in fat mass and lean
mass in HFD-fed DIO and chow-fed control
animals. D and H: daily energy intake in
HFD-fed DIO and chow-fed control animals.
Values are means SE. *P  0.05, **P 
0.05, OT vs. vehicle.
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Study 3B: Effects of 4V Treatment Cessation on Energy
Intake, Body Weight Gain, and Body Composition in DIO
CD IGS Rats
To assess the reversibility of 4V OT-elicited reductions in
weight gain, fat mass, and energy intake, these parameters
were monitored following cessation of treatment. As observed
following 3V OT treatment, animals maintained their weight
loss for 5 days following 4V OT treatment relative to 4V
vehicle controls (Fig. 5, A and B; P  0.05), but differences in
body weight and fat mass eventually disappeared (Fig. 5C; P
NS). Interestingly, this occurred despite the lack of rebound
hyperphagia (Fig. 5D; P  NS).
Study 4A: Effects of Chronic 4V OT Infusions on Energy
Intake, Body Weight, and Body Composition in DIO
Long-Evans Rats
To extend our findings to another rat model of DIO, we
examined the effects of chronic hindbrain (4V) OT adminis-
tration (27 days) in Long-Evans rats maintained on a HFD
(55). After HFD exposure for 4.5 mo, DIO Long-Evans rats
weighed 567  10 g and had a total fat mass of 194  10 g at
study onset.
Consistent with the effect of 3V OT in this rat model, we
found that chronic 4V delivery of OT elicits sustained reduc-
tions of body weight (5.8%; Fig. 6A), weight gain (Fig. 6B),
and fat mass gain (Fig. 6C; P  0.05) while preserving lean
mass, effects associated with a sustained reduction of energy
intake (Fig. 6D). These effects closely resemble those elicited
by 4V OT in CD IGS rats (Fig. 4).
Study 4B: Effects of 4V Treatment Cessation on Energy
Intake, Body Weight Gain, and Body Composition in DIO
Long-Evans Rats
After cessation of 4V infusion (minipump removal on day
27), body weight increased in both OT- and vehicle-treated
groups (Fig. 6E; P  0.05), although the weight reduction
elicited by 4V OT persisted for 4 days (Fig. 6F; P  0.05)
and the associated reduction of fat mass disappeared by the end
of the study period (27 days following minipump removal; Fig.
6G; P  NS). Recovery of lost weight in 4V OT animals was
associated with a transient increase in energy intake that was
evident only during the 3rd wk following minipump removal
(Fig. 6H; P  0.05).
Blood glucose levels following 4V infusion of OT (152.5 
4.4) did not differ from 4V vehicle-treated controls (156.3  4;
P  NS).
Study 5: Effects of Acute 3V OT Administration on TIBAT in
Rats and Mice
Given that 1) BAT activation plays a key role in control of
thermogenesis in rodents (12, 36–38), 2) reduced energy intake
cannot fully explain OT-elicited weight loss (17, 40), and 3) 3V
OT administration increases EE in rodents (59, 60), we hypothe-
sized that the antiobesity effect of OT in the CNS involves
increased EE arising from stimulation of BAT thermogenesis.
Consistent with this hypothesis, we found that, in chow-fed
Long-Evans rats, TIBAT was increased by 3V OT at 1- and 5-g
doses throughout the 2-h measurement period. Specifically, OT (1
g) increased TIBAT at 0.5, 0.75, 1 (P  0.051), 1.5, 1.75, and 2
h postinjection (data not shown; P  0.05). Similar effects were
observed with the higher (5-g) dose of 3V OT (Fig. 7A; P 0.05).
To determine whether 3V OT increases TIBAT across rodent
species, we repeated these studies in chow-fed C57BL/6J mice.
As in rats, 3V OT increased TIBAT at the 5-g dose throughout
the measurement period (Fig. 7B; P  0.05). Collectively,
these observations offer compelling evidence that BAT ther-
mogenesis increases in response to the central action of OT but
does not inform the brain area(s) responsible for this effect.
Study 6A: Effects of Acute 4V OT Administration on TIBAT
in Rats
To investigate whether hindbrain OTRs contribute to the
effects of 3V OT to stimulate BAT thermogenesis, we mea-
sured the effect of 4V administration of OT on TIBAT in
chow-fed Long-Evans rats. Consistent with this hypothesis,
TIBAT increased following 4V administration of OT (1 and 5
g), and this effect was again sustained throughout the 2-h
monitoring period in a manner similar to that observed follow-
ing 3V OT (Fig. 8A; P  0.05).
Study 6B: Effects of 4V OT Administration on TIBAT
Following 4V OT Antagonist Treatment in Rats
To confirm that this effect of 4V OT to increase TIBAT is
mediated specifically through OTRs, chow-fed Long-Evans rats
were treated with a 4V injection of the OTR antagonist
d(CH2)51,Tyr(Me)2,Orn8]-OT or vehicle before a second 4V injec-
tion of OT or vehicle. As expected, the effect of 4V OT to increase
TIBAT was fully blocked following administration of a dose of the
OTR antagonist that did not alter TIBAT when given alone (Fig. 8B).
Two-way ANOVA revealed a significant main effect of 4V
OT [(F(1,33)  8.137, P  0.05] and 4V OTR antagonist
[F(1,33)  12.772, P  0.05] and a significant interactive
effect of the 4V OTR antagonist to block the effects of 4V OT
on TIBAT [F(1,33)  6.709, P  0.05].
These findings indicate that hindbrain (4V) administration of
OT elevates TIBAT through an OTR-dependent mechanism.
Study 6C: Effects of Acute 4V OT Administration on TIBAT in
DIO Rats
To test whether DIO impacts the TIBAT response to central
OT, the study was repeated in the HFD-fed Long-Evans rat
model. We found that 4V administration of OT (5 g) in-
Table 2. Serum measurements following 3V infusions of OT
or vehicle in DIO mice from study 7
Chow HFD
Veh OT Veh OT
Leptin, ng/ml 1.9  0.6a 1.4  0.2a 22.9  5.4b 14.9  4.0b
Insulin, ng/ml 0.2  0.03a 0.2  0.02a 0.5  0.14b 0.5  0.14b
FGF-21, pg/ml 138  26a 134  14a 694  156b 652  152b
Irisin, g/ml 2.3  0.2 2.0  0.1 1.9 0.2 2.1  0.2
Blood glucose,
mg/dl 197  7.5a,b 190  12.0b 228  15.9a 211  4.7a,b
FFA, meq/l 0.3  0.04a 0.2  0.01a,c 0.2  0.05c 0.2  0.02c
Total cholesterol,
mg/dl 122  6.6a 93  6.7a 230  17.4b 196  22.7c
Values means  SE; n  3–12/group. Different superscript letters denote
significant differences between treatments; shared letters denote values that are
not significantly different from one another.
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creased TIBAT in a manner largely comparable to that observed
in nonobese, chow-fed rats (Fig. 8C).
Study 6D: Effects of Chronic 3V OT Administration on TIBAT
in DIO Rats
To determine if effects on TIBAT following acute 3V or 4V
OT administration are also detected with chronic OT admin-
istration, TIBAT was measured during chronic 3V delivery
during the initial period of OT-elicited weight loss (over the
first 3 days) in the DIO Long-Evans rat model. We found that
chronic 3V infusion of OT (16 nmol/day) increased TIBAT
during infusion days 2 and 3, a period that coincides with the
initial weight-lowering effect following chronic 3V adminis-
tration of OT (Fig. 1B). These findings support a role for
Fig. 4. Effects of chronic 4V OT infusions
on energy intake, body weight gain, and
body composition in DIO and chow-fed CD
IGS rats. Ad libitum-fed rats were main-
tained on the HFD (60% of kcal from fat;
n  12–15/group) or chow (n  7–11/
group) for 4.5 mo before receiving continu-
ous infusions of vehicle or OT (16 nmol/
day). A and E: change in body weight in
HFD-fed DIO and chow-fed control animals.
B and F: change in body weight gain in
HFD-fed DIO and chow-fed control animals.
C and G: change in fat mass and lean mass in
HFD-fed DIO and chow-fed control animals.
D and H: daily energy intake in HFD-fed
DIO and chow-fed control animals. Values
are means SE. *P  0.05, OT vs. vehicle.
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stimulation of BAT thermogenesis in OT-elicited weight loss
(Fig. 9).
DISCUSSION
The goal of the current studies was to determine 1) whether,
during chronic infusion, hindbrain (4V) OT recapitulates the
ability of 3V OT to elicit sustained weight loss in rodent
models of DIO and 2) whether this effect involves increased
IBAT thermogenesis in addition to reduced energy intake. Our
findings demonstrate that, in a rat model of DIO, chronic 4V
administration of OT effectively recapitulates the antiobesity
effect elicited by infusion into the 3V. We also report that that
OT injection into the 3V or 4V acutely elevates TIBAT, a
functional readout of BAT thermogenesis in vivo, and that
these effects are mediated via an OTR-dependent mechanism.
Collectively, these findings support the hypothesis that OT
action in the hindbrain evokes weight loss in DIO rodents by
reducing HFD intake while simultaneously increasing BAT
thermogenesis.
Our finding that chronic hindbrain (4V) administration of
OT evokes weight loss in DIO HFD-fed rats extends previ-
ous evidence from studies in which 1) 4V OT administered
acutely to rats reduced standard chow intake (27, 43), and
2) chronic OT administration into the lateral ventricle or 3V
of rats and mice reduced HFD intake and body weight (7,
17, 59, 60). While activation of OTRs in the arcuate nucleus
(34), ventromedial hypothalamus (VMH) (41), or other
forebrain areas may contribute to the weight-reducing ef-
fects of 3V OT, our finding that 4V administration recapit-
ulates these effects suggests that activation of hindbrain
OTRs is sufficient to explain this effect. While it is con-
ceivable that some effects of 4V administration resulted
from reflux into the 3V and activation of forebrain OTRs,
such an effect could have made only a small contribution to
the effects we observed. This assertion is based on previous
evidence demonstrating that 1) angiotensin II, which acts
through forebrain type 1 (AT1) receptors, fails to stimulate
drinking behavior following 4V administration (21) and 2)
4V administration of India ink does not result in ink distri-
bution rostral to the caudal brain stem (22, 25). Neverthe-
less, future studies to exclude this possibility are warranted,
as are studies to determine whether hindbrain OTRs are
necessary for the antiobesity effects of OT. Specifically, it
will be important to address the extent to which deletion of
NTS OTRs in both mice and rats fed a HFD 1) blocks the
effects of chronic 4V OT to reduce HFD intake, increase
EE, and induce weight loss and 2) predisposes animals to
DIO and associated metabolic defects.
Our finding that BAT thermogenesis increases following 4V
OT administration implicates hindbrain and/or spinal cord
OTR populations in these effects. This interpretation is con-
sistent with anatomic evidence indicating that OT neuronal cell
bodies in the parvocellular neurons of the PVN are positioned
to control sympathetic nervous system (SNS) outflow to IBAT
to stimulate BAT thermogenesis through direct descending
projections to the hindbrain NTS (47, 50) and/or spinal cord
(50), sites that can control SNS outflow to IBAT and are linked
to the control of BAT thermogenesis (2, 13). Theoretically, OT
action on NTS neurons could influence BAT thermogenesis
directly via projections to the spinal cord (whether OTR-
expressing premotor NTS neurons project to the spinal cord
remains to be determined) or indirectly via projections to
sympathetic premotor neurons in the raphe pallidus (RPa) (31).
Neurons in the RPa regulate SNS control of BAT via projec-
tions to sympathetic preganglionic neurons in the spinal cord in
a circuit that is essential for normal thermoregulation (13, 36,
38). Since neurons in this brain area also express OTRs that are
activated by cold exposure (30), OT-mediated BAT thermo-
genesis may also involve activation of OTRs within the RPa.
Consistent with this hypothesis is evidence that, in mice that
lack OTRs, virally mediated rescue of OTRs, specifically in the
rostral RPa, is sufficient to rescue impairments of thermogen-
esis and IBAT activation by cold exposure (30). Histological
analysis revealed that these effects coincided with “scarce”
accumulation of lipid droplets in IBAT (30) compared with the
excessive number of lipid droplets in IBAT of OTR-null mice
(consistent with hypoactivity of BAT and impaired thermogen-
esis) (54). Future studies are warranted to more clearly delin-
eate the OTR-expressing neuronal population(s) responsible
for OT-induced BAT thermogenesis and determine the extent
to which the antiobesity effect of OT depends on this mecha-
nism.
The more robust effect of OT in DIO animals may be
explained by a number of factors, including macronutrient
preference toward fat and/or the presence of cholesterol in the
HFD, which may enhance the affinity state of the OTR (3, 24).
Fig. 5. Effects of 4V OT treatment cessation on body weight, body weight gain, body composition, and energy intake in DIO CD IGS rats. Minipumps were
removed on day 27 (indicated by arrow) from a subset of DIO rats (n  6/group) that had received continuous infusions of vehicle or OT (16 nmol/day). Ad
libitum-fed rats were maintained on the HFD (60% of kcal from fat) throughout the 27-day washout period. A: change in body weight in HFD-fed DIO animals
during washout. B: change in body weight gain in HFD-fed DIO animals during washout. C: change in fat mass and lean mass in HFD-fed DIO animals during
washout. D: daily energy intake in HFD-fed DIO animals during washout. Values are means  SE. *P  0.05, OT vs. vehicle.
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Our previous work sought to gain insight into whether the
ability of OT to induce weight loss is influenced by 1) diet
composition, 2) adiposity, or 3) body weight (7), as well as
whether 3V OT is sufficient to prevent DIO, induce weight loss
in DIO rodents, or both. Our finding that chronic 3V OT
preferentially reduces energy intake and prevents weight gain
in HFD-fed DIO rat models, even when their body weight and
adiposity are comparable to chow-fed controls (7), suggests
that the selective nature of the weight-reducing effect of central
OT is influenced more by diet composition than by differences
in body weight or adiposity. Whether the same is true follow-
ing 4V OT treatment is a priority for future studies.
Fig. 6. Effects of chronic 4V OT infusions
and 4V OT treatment cessation on energy
intake, body weight gain, and body compo-
sition in DIO Long-Evans rats. Ad libitum-
fed rats were maintained on the HFD (60% of
kcal from fat; n  6–8/group) for 4.5 mo
before receiving continuous infusions of ve-
hicle or OT (16 nmol/day). Minipumps were
removed on day 27 (indicated by arrow) from
a subset of DIO rats (n  4/group), and
animals were maintained on the HFD
throughout the 27-day washout period. A and
E: change in body weight in HFD-fed DIO
animals during treatment and washout. B and
F: change in body weight gain in HFD-fed
DIO animals during treatment and washout.
C and G: change in fat mass and lean mass in
HFD-fed DIO animals during treatment and
washout. D and H: daily energy intake in
HFD-fed DIO animals during treatment and
washout. Values are means SE. *P 0.05,
OT vs. vehicle or post-OT vs. postvehicle.
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Rosenbaum and colleagues propose that weight loss in obese
humans produces a state of relative leptin deficiency that
activates orexigenic and energy conservation mechanisms to
limit weight loss and promote weight regain (48, 49). In this
context, it is noteworthy that 1) weight loss induced by 4V OT
persists for 4–5 days following cessation of treatment and 2)
animals do not increase their food intake during this time. Thus
the action of OT in the hindbrain may maintain weight loss by
preventing the rebound hyperphagia that is normally associated
with energy deficit. Similar effects were observed following
cessation of OT treatment in CD IGS rats (7), DIO mice (33),
and nonhuman primates (4). By comparison, rebound hy-
perphagia occurs within 1–3 days following treatment cessa-
tion with melanotan II (44), exendin-4 (46), or an exendin-4/
peptide YY-(3–36) cocktail (46). The prolonged carryover
effect of OT is not unique to effects on energy balance,
however, as the effects of OT on exploratory and antiaggres-
sive behavior also persist for 7 days following cessation of
treatment in male rats (10). A priority for future work is
identification of energy balance neurocircuits on which OT acts
to maintain weight loss following treatment cessation.
One caveat to these considerations is that cessation of OT
treatment elicited rebound hyperphagia in the Long-Evans DIO
rat model, but not in CD IGS rats. These findings are consistent
with a recent study that compared mechanisms accounting for
rebound weight gain (i.e., rebound hyperphagia with or without
reduced EE) in Long-Evans and Sprague-Dawley rats (CD IGS
rats are derived from the Sprague-Dawley rat strain; personal
communication, Charles River Laboratories) that were allowed
to refeed following a prolonged bout of calorie restriction (20).
Evans et al. found that Long-Evans rats display an immediate
rebound hyperphagia that persists for8 days and, in addition,
Fig. 7. Effects of 3V OT administration on interscapular brown adipose tissue
temperature (TIBAT) in rats and mice. A: TIBAT in rats that received acute 3V
injections of OT (5 g/l) or vehicle (n  10/group). B: TIBAT in mice that
received an acute 3V injection of OT (5 g/l; n  5/group). Values are
means  SE. *P  0.05, OT vs. vehicle.
Fig. 8. Effects of 4V OT administration on TIBAT in chow-fed and HFD-fed DIO Long-Evans rats. A: TIBAT in rats that received acute 4V injections of OT (5
g/l) or vehicle (n  12/group). B: TIBAT in rats that received an acute 4V injection of OT receptor antagonist (OTRA, 10 g/2 l) before OT (5 g/l; n 
12/group). C: TIBAT in DIO rats that received an acute 4V injection (5 g/l) or vehicle (n  4/group). Values are means SE. *P  0.05, OT vs. vehicle.
Fig. 9. Effects of chronic 3V OT administration on TIBAT in DIO Long-Evans
rats. TIBAT was measured daily during 72-h infusions of OT (16 nmol/day) or
vehicle in 3-h-fasted rats (n  8–10/group). Values are means SE. *P 
0.05, OT vs. vehicle.
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have a more immediate normalization of EE following calorie
restriction (20). In contrast, Sprague-Dawley rats show only a
mild and transient rebound hyperphagia that was completely
resolved by day 2. In addition, the Sprague-Dawley rats
showed prolonged suppression of EE that persisted for 4
days into the refeeding period. These observations are consis-
tent with our finding that, following cessation of OT treatment
(and prolonged weight loss), the Long-Evans DIO rat model,
but not CD IGS rats, showed a rebound hyperphagia. These
findings suggest that mechanisms underlying recovery of lost
weight following OT treatment vary with genetic background
strain. Future studies that delineate energy balance neurocir-
cuits on which OT acts to elicit its effects on energy homeo-
stasis may shed light on these strain differences.
Perspectives and Significance
Obesity and its associated metabolic complications (15, 19,
26) are major health concerns (51). According to the World
Health Organization, global obesity prevalence rates have
increased at least twofold since 1980, with ~1.9 billion adults
classified as being overweight as of 2014 (Fact Sheet No. 311,
World Health Organization). In the United States alone, obe-
sity impacts ~78 million adults and 12.5 million children and
adolescents (42). Given the limited efficacy of current treat-
ment options, the need for new, more effective approaches is
urgent.
Our current work documents combined effects of OT action
in the hindbrain to reduce energy intake and increase BAT
thermogenesis, with the result that body fat content is reduced
in a manner that is sustained through several weeks of treat-
ment. Moreover, OT-induced weight loss cannot be attributed
to an aversive effect, is not observed in nonobese rats fed
standard chow, and spares lean mass. Each of these features is
highly desirable for an obesity therapeutic agent, especially
given that, in humans and nonhuman primates, OT can be
administered intranasally (14, 32, 61). This delivery method
holds promise as an appealing, noninvasive strategy to target
OTRs in the CNS that regulate appetite and/or BAT thermo-
genesis (23, 53).
Since previous effects of intranasal OT on energy balance
have focused primarily on food intake, further studies are
warranted to identify the extent to which intranasal OT in-
creases BAT thermogenesis and EE in rodent and nonhuman
primate models and the extent to which hindbrain OTRs
mediate these effects. Intranasal OT may also be effective for
prevention of weight gain among those at risk, including
patients taking certain antipsychotic medications (52). For
example, the effect of the antipsychotic olanzapine to cause
marked weight gain involves increased intake and reduced EE
and BAT thermogenesis (52). Thus intranasal OT could poten-
tially be used as an adjunct to prevent the weight gain associ-
ated with these drugs. Future studies that address the extent to
which chronic intranasal OT can safely and effectively reverse
or prevent obesity in humans are a priority.
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